There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.

There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.

Bloomberg's Joe Weisenthal and Tracy Alloway explore the most interesting topics in finance, markets and economics. Join the conversation every Monday and Thursday.

Bloomberg's Joe Weisenthal and Tracy Alloway explore the most interesting topics in finance, markets and economics. Join the conversation every Monday and Thursday.

Bloomberg's Joe Weisenthal and Tracy Alloway analyze the weird patterns, the complex issues and the newest market crazes. Join the conversation every Tuesday and Thursday for interviews with the most interesting minds in finance, economics and markets.

Odd Lots

On Bloomberg’s Odd Lots podcast Joe Weisenthal and Tracy Alloway explore the most interesting topics in finance, markets, and economics. Join the conversation every Monday and Thursday. 

On Bloomberg’s Odd Lots podcast Joe Weisenthal and Tracy Alloway explore the most interesting topics in finance, markets, and economics. Join the conversation every Monday and Thursday.

Here's How the New Weight Loss Drugs Could Change Everything

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b5ae666e-8a28-42ab-b0c2-b060012c70b9/transcript

Over the past two weeks, two New York City office buildings have become major talking points in the market for commercial real estate. Troubles at 1740 Broadway led to the first loss in the AAA-rated tranche of a commercial mortgage bond since the financial crisis. Meanwhile, issues at 1440 Broadway recently propelled the serious delinquency rate for office loans to its highest level since early 2007. So what do these two properties tell us about the outlook for commercial real estate, and how these deals work? On this episode of Lots More, we bring back Hiten Samtani, founder of ten31 Media, to talk about the future of these buildings, as well as their storied history.

Over the past two weeks, two New York City office buildings have become major talking points in the market for commercial real estate. Troubles at 1740 Broadway led to the first loss in the AAA-rated tranche of a commercial mortgage bond since the financial crisis. Meanwhile, issues at 1440 Broadway recently propelled the serious delinquency rate for office loans to its highest level since early 2007. So what do these two properties tell us about the outlook for commercial real estate, and how these deals work? On this episode of Lots More, we bring back Hiten Samtani, founder of <a href="https://ten31.beehiiv.com/">ten31 Media</a>, to talk about the future of these buildings, as well as their storied history.

Lots More on the Two Troubled NYC Office Buildings Everyone's Talking About

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/0acdc069-ef44-4b3d-b9df-b180014e676d/transcript

The modern electricity grid is a weird thing. The delivery of electricity is a natural monopoly, for kind of obvious reasons. Despite that, we still attempt to shoehorn market-based mechanisms into the system. Many utilities are shareholder-owned, yet heavily regulated. In many markets around the country, producers of natural gas, wind, coal, nuclear, solar and so on, compete to sell their electricity into the grid. Now that we're looking for ways to decarbonize the grid, we're running headlong into complications and perverse outcomes of what we've built. On this episode of the podcast, we speak with Matt Huber, a professor at Syracuse University, and Fred Stafford, a pseudonymous writer who talks about energy markets, grid history, and nuclear power. We talk to them about how we got the current grid, and why nuclear energy in particular is squeezed out of existing markets.

The modern electricity grid is a weird thing. The delivery of electricity is a natural monopoly, for kind of obvious reasons. Despite that, we still attempt to shoehorn market-based mechanisms into the system. Many utilities are shareholder-owned, yet heavily regulated. In many markets around the country, producers of natural gas, wind, coal, nuclear, solar and so on, compete to sell their electricity into the grid. Now that we're looking for ways to decarbonize the grid, we're running headlong into complications and perverse outcomes of what we've built. On this episode of the podcast, we speak with Matt Huber, a professor at Syracuse University, and Fred Stafford, a pseudonymous writer who talks about energy markets, grid history, and nuclear power. We talk to them about how we got the current grid, and why nuclear energy in particular is squeezed out of existing markets.

The Big Problem With the Modern Electricity Grid

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d67f5194-d98d-45cc-b924-b17f0130e2fe/transcript

The cost of solar has been plunging for years. Everyday there's a new headline about growing installation of renewables or batteries, or some other sign of progress when it comes to decarbonization. But there's still a long way to go and, in the meantime, the US continues to add new fossil fuel generation. So is there something wrong with the mechanisms we're using to change our energy mix? On this episode, we're speaking with Brett Christophers. He's a professor at Uppsala University and the author of the new book The Price is Wrong: Why Capitalism Won't Save The Planet. His basic argument is that using market-based mechanisms will conflict with the imperative to clean the grid and that the incentives aren't aligned for both goals. We discuss the economics of clean energy production, and why they don't lend themselves to a rapid buildout.

The cost of solar has been plunging for years. Everyday there's a new headline about growing installation of renewables or batteries, or some other sign of progress when it comes to decarbonization. But there's still a long way to go and, in the meantime, the US continues to add new fossil fuel generation. So is there something wrong with the mechanisms we're using to change our energy mix? On this episode, we're speaking with Brett Christophers. He's a professor at Uppsala University and the author of the new book The Price is Wrong: Why Capitalism Won't Save The Planet. His basic argument is that using market-based mechanisms will conflict with the imperative to clean the grid and that the incentives aren't aligned for both goals. We discuss the economics of clean energy production, and why they don't lend themselves to a rapid buildout.

Are We Doing Decarbonization Totally the Wrong Way?

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1b197e8c-838f-4bdd-84b4-b17e0104ce2b/transcript

Here's How the New Weight Loss Drugs Could Change Everything

In 1 playlist(s)

Odd Lots

Social links

Follow podcast

Recent clips